Clinical Study
FIREFLY-1
The description and purpose of the study drug is to research the use of an investigational product labeled NA- IP (DAY 101- formerly TAK-580/MLN2480) to treat Low-Grade Glioma and other advanced solid tumors in pediatric and age-of-majority participants
For more information contact:
Sophia Ochoa
sophia.ochoa@hsc.utah.edu
801-587-7463
IRB#: IRB_00138633
| PI: Nicholas Whipple
| Department: PEDIATRIC HEMATOLOGY/ONCOLOGY
| Approval Date: 2021-08-04 06:00:00
Study Categories: All Cancer Studies
| Specialties: Pediatric Hematology & Oncology
Who can participate?
Gender: All
Age: All Ages
Volunteers: Volunteers with special conditions
Location: In Person
Will I be paid for my time?
Yes